These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

177 related articles for article (PubMed ID: 28719063)

  • 21. Plasminogen activator inhibitor-1 released from activated platelets plays a key role in thrombolysis resistance. Studies with thrombi generated in the Chandler loop.
    Stringer HA; van Swieten P; Heijnen HF; Sixma JJ; Pannekoek H
    Arterioscler Thromb; 1994 Sep; 14(9):1452-8. PubMed ID: 8068607
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Blood Accessibility to Fibrin in Venous Thrombosis is Thrombus Age-Dependent and Predicts Fibrinolytic Efficacy: An In Vivo Fibrin Molecular Imaging Study.
    Stein-Merlob AF; Kessinger CW; Erdem SS; Zelada H; Hilderbrand SA; Lin CP; Tearney GJ; Jaff MR; Reed GL; Henke PK; McCarthy JR; Jaffer FA
    Theranostics; 2015; 5(12):1317-27. PubMed ID: 26516370
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Multimodal microwheel swarms for targeting in three-dimensional networks.
    Zimmermann CJ; Herson PS; Neeves KB; Marr DWM
    Sci Rep; 2022 Mar; 12(1):5078. PubMed ID: 35332242
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Plasma tissue-type plasminogen activator increases fibrinolytic activity of exogenous urokinase-type plasminogen activator.
    Shenkman B; Livnat T; Budnik I; Tamarin I; Einav Y; Martinowitz U
    Blood Coagul Fibrinolysis; 2012 Dec; 23(8):729-33. PubMed ID: 22918041
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Recognition of Plasminogen Activator Inhibitor Type 1 as the Primary Regulator of Fibrinolysis.
    Urano T; Suzuki Y; Iwaki T; Sano H; Honkura N; Castellino FJ
    Curr Drug Targets; 2019; 20(16):1695-1701. PubMed ID: 31309890
    [TBL] [Abstract][Full Text] [Related]  

  • 26. TM5275 prolongs secreted tissue plasminogen activator retention and enhances fibrinolysis on vascular endothelial cells.
    Yasui H; Suzuki Y; Sano H; Suda T; Chida K; Dan T; Miyata T; Urano T
    Thromb Res; 2013 Jul; 132(1):100-5. PubMed ID: 23611258
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Phospholipid barrier to fibrinolysis: role for the anionic polar head charge and the gel phase crystalline structure.
    Váradi B; Kolev K; Tenekedjiev K; Mészáros G; Kovalszky I; Longstaff C; Machovich R
    J Biol Chem; 2004 Sep; 279(38):39863-71. PubMed ID: 15254044
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Effects of colloid and crystalloid solutions on endogenous activation of fibrinolysis and resistance of polymerized fibrin to recombinant tissue plasminogen activator added ex vivo.
    Mittermayr M; Streif W; Haas T; Fries D; Velik-Salchner C; Klingler A; Innerhofer P
    Br J Anaesth; 2008 Mar; 100(3):307-14. PubMed ID: 18158312
    [TBL] [Abstract][Full Text] [Related]  

  • 29. High accumulation of plasminogen and tissue plasminogen activator at the flow surface of mural fibrin in the human arterial system.
    Sasajima T; Takano Y; Hiraishi Y; Goh K; Inaba M; Azuma N; Sasajima Y; Yamazaki K; Yamamoto H
    J Vasc Surg; 2000 Aug; 32(2):374-82. PubMed ID: 10917998
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Fibrin-specific and effective clot lysis requires both plasminogen activators and for them to be in a sequential rather than simultaneous combination.
    Pannell R; Li S; Gurewich V
    J Thromb Thrombolysis; 2017 Aug; 44(2):210-215. PubMed ID: 28600623
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Initiation and regulation of fibrinolysis in human plasma at the plasminogen activator level.
    Wun TC; Capuano A
    Blood; 1987 May; 69(5):1354-62. PubMed ID: 3105619
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The biochemical and physical process of fibrinolysis and effects of clot structure and stability on the lysis rate.
    Weisel JW; Litvinov RI
    Cardiovasc Hematol Agents Med Chem; 2008 Jul; 6(3):161-80. PubMed ID: 18673231
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Platelets and endothelial cells act in concert to delay thrombolysis--evidence from an in vitro model of the human occlusive thrombus.
    Hantgan RR; Jerome WG; Handt S
    Thromb Haemost; 1998 Mar; 79(3):602-8. PubMed ID: 9531049
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Fibrinolysis: a Misunderstood Natural Defense Whose Therapeutic Potential Is Unknown.
    Gurewich V
    Cardiovasc Drugs Ther; 2019 Dec; 33(6):749-753. PubMed ID: 31897763
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Imaging analyses of coagulation-dependent initiation of fibrinolysis on activated platelets and its modification by thrombin-activatable fibrinolysis inhibitor.
    Brzoska T; Suzuki Y; Sano H; Suzuki S; Tomczyk M; Tanaka H; Urano T
    Thromb Haemost; 2017 Apr; 117(4):682-690. PubMed ID: 28150854
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A structural and dynamic investigation of the facilitating effect of glycoprotein IIb/IIIa inhibitors in dissolving platelet-rich clots.
    Collet JP; Montalescot G; Lesty C; Weisel JW
    Circ Res; 2002 Mar; 90(4):428-34. PubMed ID: 11884372
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Clot penetration and retention by plasminogen activators promote fibrinolysis.
    Marcos-Contreras OA; Ganguly K; Yamamoto A; Shlansky-Goldberg R; Cines DB; Muzykantov VR; Murciano JC
    Biochem Pharmacol; 2013 Jan; 85(2):216-22. PubMed ID: 23098998
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Biochemical and biophysical conditions for blood clot lysis.
    Sabovic M; Blinc A
    Pflugers Arch; 2000; 440(5 Suppl):R134-6. PubMed ID: 11005642
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Effect of locally applied tissue-type plasminogen activator on venous fibrinolytic activity: in vitro and in vivo investigations.
    Underwood MJ; More RS; Gershlick AH; de Bono DP
    Cardiovasc Res; 1993 Dec; 27(12):2270-3. PubMed ID: 8313438
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Factors influencing recanalization of thrombotic venous occlusions.
    Poredoš P; Poredoš P; Jezovnik MK
    Vasa; 2020 Jan; 49(1):17-22. PubMed ID: 31134852
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.